DBCG: The Danish Breast Cancer Cooperative Group – a 30-year struggle for better breast cancer treatment in Denmark

References

• Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907; 46: 1
   PubMedGoogle Scholar
• McWhirter R. The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. Brit J Radiol 1948; 21: 599–610
   PubMed Web of Science ®Google Scholar
• Johansen H, Kaae S, Jensen M-B, Mouridsen HT. Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen Breast Cancer randomised study. Acta Oncol 2008; 47: 633–38
   PubMed Web of Science ®Google Scholar
• Nissen-Meyer R, Kjellgren K, Malmio K, Månsson B, Norin T. Surgical adjuvant chemotherapy: Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 1978; 41: 2088–98
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995; 332: 901–6
   PubMed Web of Science ®Google Scholar
• Fisher B, Jeong JH, Anderson S, Wolmark N. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004; 96: 1823–31
   PubMedGoogle Scholar
• Fisher B. Laboratory and clinical research in breast cancer–a personal adventure: The David A. Karnofsky memorial lecture. Cancer Res 1980; 40: 3863–74
   PubMed Web of Science ®Google Scholar
• Einhorn J, Larsson LG. Neoplasm medical care and radiotherapy organization] Lakartidningen 1970; 67: 1181–93
   PubMedGoogle Scholar
• Peckham MJ. Clinical oncology: The future of radiotherapy and medical oncology. Lancet 1981; 1: 886–7
   PubMedGoogle Scholar
• Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group – DBCG: History, organisation, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008; 47: 497–505
   PubMed Web of Science ®Google Scholar
• Møller S, Jensen M-B, Ejlertsen B, Bjerre KG, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines programmes of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008; 47: 506–24
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Bjerre KD, Christiansen P, Jensen M-B, Møller S. Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG registry. Acta Oncol 2008; 47: 525–36
   PubMed Web of Science ®Google Scholar
• Talman M-LM, Rasmussen BR, Andersen J, Christensen IJ. Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications. Acta Oncol 2008; 47: 789–94
   PubMed Web of Science ®Google Scholar
• Thorpe SM, Poulsen HS, Pedersen KO, Rose C. Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark. Eur J Cancer Clin Oncol 1988; 24: 1263–9
   PubMedGoogle Scholar
• Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949–55
   PubMed Web of Science ®Google Scholar
• Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641–8
   PubMed Web of Science ®Google Scholar
• Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007; 82: 247–53
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006; 24: 2268–75
   PubMed Web of Science ®Google Scholar
• Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 1994; 12: 2229–34
   PubMed Web of Science ®Google Scholar
• Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials. Lancet 1999; 354: 1425–30
   PubMed Web of Science ®Google Scholar
• Overgaard M, Juul Christensen J. Postoperative Radiotherapy in DBCG during 30 Years. Techniques, indications and clinical radiobiological perspectives. Acta Oncol 2008; 47: 639–53
   PubMed Web of Science ®Google Scholar
• Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557–65
   PubMed Web of Science ®Google Scholar
• Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s–1990s. Int J Radiat Oncol Biol Phys 2007; 69: 1484–95
   PubMed Web of Science ®Google Scholar
• Overgaard M, Bentzen SM, Christensen JJ, Madsen EH. The value of the NSD formula in equation of acute and late radiation complications in normal tissue following 2 and 5 fractions per week in breast cancer patients treated with postmastectomy irradiation. Radiother Oncol 1987; 9: 1–11
   PubMed Web of Science ®Google Scholar
• Johansen J, Overgaard J, Blichert-Toft M, Overgaard M. Treatment of morbidity associated with the management of the axilla in breast-conserving therapy. Acta Oncol 2000; 39: 349–54
   PubMed Web of Science ®Google Scholar
• Højris I, Andersen J, Overgaard M, Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncol 2000; 39: 355–72
   PubMed Web of Science ®Google Scholar
• Johansen J, Overgaard J, Rose C, Engelholm SA, Gadeberg CC, Kjaer M, et al. Danish Breast Cancer Cooperative Group (DBCG) and the DBCG Radiotherapy Committee. Cosmetic outcome and breast morbidity in breast-conserving treatment–results from the Danish DBCG-82TM national randomized trial in breast cancer. Acta Oncol 2002; 41: 369–80
   PubMed Web of Science ®Google Scholar
• Johansen J, Overgaard J, Overgaard M. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Acta Oncol 2007; 46: 525–33
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Overgaard M. Early and late normal tissue injury after postmastectomy radiotherapy. Recent Results Cancer Res 1993; 130: 59–78
   PubMedGoogle Scholar
• Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles?. Acta Oncol 2005; 44: 801–15
   PubMed Web of Science ®Google Scholar
• Rødningen OK, Børresen-Dale AL, Alsner J, Hastie T, Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol 2008; 86: 314–20
   PubMed Web of Science ®Google Scholar
• Alsner J, Andreassen CN, Overgaard J. Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008; 18: 126–35
   PubMed Web of Science ®Google Scholar
• Jensen AR, Garne JP, Storm HH, Ewertz M, Cold S, Alvegaard T, Overgaard J. Stage and survival in breast cancer patients in screened and non-screened Danish and Swedish populations. Acta Oncol 2003; 42: 701–9
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–57
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol 2007; 25: 5715–22
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, et al. BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9: 23–8
   PubMed Web of Science ®Google Scholar
• Offersen, BV, Overgaard, M, Kroman, K, Overgaard, J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: A systematic review. ( submitted).
   Google Scholar
• Henriksen KL, Sonne-Hansen K, Kirkegaard T, Frogne T, Lykkesfeldt AE. Development of new predictive markers for endocrine therapy and resistance in breast cancer. Acta Oncol 2008; 47: 795–801
   PubMed Web of Science ®Google Scholar
• Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of Topoiso-merase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483–90
   PubMed Web of Science ®Google Scholar
• Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Knudsen H, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008; 47: 725–34
   PubMed Web of Science ®Google Scholar
• Kyndi, M, Sørensen, FB, Knudsen, H, Overgaard, M, Nielsen, HM, Andersen, J, et al. Tissue micro arrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol 2008; 47:591–99
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419–26
   PubMed Web of Science ®Google Scholar
• Thomassen M, Tan Q, Eiriksdottir F, Bak M, Cold S, Kruse TA. Prediction of metastasis from low-malignant breast cancer by gene expression profiling. Int J Cancer 2007; 120: 1070–5
   PubMed Web of Science ®Google Scholar
• Thomassen M, Hansen TvO, Borg Å, Lianee HT, Wikman F, Pedersen IS, et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol 2008; 47: 772–77
   PubMed Web of Science ®Google Scholar
• Offersen, BV, Riisbro, R, Knoop, A, Brünner, N, Overgaard, J; Danish Breast Cancer Cooperative Group (DBCG) Tumor Biology Committee. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer. Acta Oncol 2007;46:782–91.
   PubMed Web of Science ®Google Scholar
• Würtz SØ, Schrohl A-S, Mouridsen H, Brünner N. TIMP-1 as a tumor marker in breast cancer – An update. Acta Oncol 2008; 47: 580–90
   PubMed Web of Science ®Google Scholar
• Offersen BV, Alsner J, Olsen KE, Riisbro R, Brunner N, Sørensen FB, et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008; 47: 618–32
   PubMed Web of Science ®Google Scholar
• Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børrensen-Dale A-L, et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008; 47: 600–7
   PubMed Web of Science ®Google Scholar
• Madsen AH, Jensen AR, Christiansen P, Garne JP, Cold S, Ewertz M, et al. Does the introduction of sentinel node biopsy increase the number of node positive patients with early breast cancer? A population based study form the Danish Breast Cancer Cooperative Group. Acta Oncol 2008; 47: 239–47
   PubMed Web of Science ®Google Scholar
• Friis E, Galatius H, Garne JP. Organized nation-wide implementation of sentinel lymph node biopsy in Denmark. Acta Oncol 2008; 47: 556–60
   PubMed Web of Science ®Google Scholar
• Christiansen P, Friis E, Balslev E, Jensen D, Møller S. Sentinel node biopsy in breast cancer: Five years experience from Denmark. Acta Oncol 2008; 47: 561–68
   PubMed Web of Science ®Google Scholar
• Klinisk kræftforskning i Danmark. KOF-udvalget nedsat af Statens Sundhedsvidenskabelige Forskningsråd. Forskningsstyrelsen. 2004; pp 1–67.
   Google Scholar